SEC Form 4 · accession 0001209191-18-054606
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell Skibsted
Officer — Chief Financial Officer
Period of report
Oct 4, 2018
Accepted (ET)
Oct 9, 2018 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Oct 4, 2018 | M | 11,250 | $0.00 | A | 13,250 | D | |
| Common Shares, no par valueF3,F2 | Oct 4, 2018 | F | 3,891 | $2.22 | D | 9,359 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4 | $0.00 | Oct 4, 2018 | M | 11,250 | D | — | — | Common Shares | 11,250 | 33,750 | D |
Explanation of responses
- F1Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018.
- F2Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
- F3Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,250 RSUs, the grant of which was previously reported on a Form 8-K.
- F425% of the RSUs granted on May 24, 2018 vested on October 4, 2018, then the remaining 75% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.